drugset / Trial / NCT04735510
Novel Use of Restasis and PROSE Devices
NaSingle-groupOpen-labelTreatment
Summary
The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD).
Timeline
- Start
- 2021-05
- Primary completion
- 2021-09
- Completion
- 2021-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 0.05 % | — |